-
2023-506921-12-00
5
2018-12-27
ER+/HER2- Breast Cancer
-
2023-506125-10-00
5
2018-12-24
Multiple Myeloma
-
2022-501485-22-00
5
2018-12-18
Myelodysplastic syndrome (MDS)
-
2024-513912-89-00
10
2018-12-13
Primary Or Secondary (Post-PV MF or Post-ET-MF) Myelofibrosis (MF) Wit
-
2023-510009-16-00
9
2018-12-04
Acute Myeloid Leukemia
-
2023-508463-71-00
5
2018-11-30
Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic L
-
2024-510605-28-00
5
2018-11-27
Stage 3 or 4 Non-mucinous Epithelial Ovarian Cancer
-
2022-501966-23-00
5
2018-09-11
Resected High-Risk Stage II Melanoma
-
2024-510713-15-00
4
2018-07-30
Localised and operable soft tissue sarcomas
-
2022-503042-42-00
4
2018-07-23
Pulmonary Arterial Hypertension
-
2023-504581-29-00
7
2018-04-26
Multiple myeloma
-
2023-503469-49-00
5
2018-04-19
Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL)
-
2024-513070-21-00
4
2018-02-15
Relapsed Acute Lymphoblastic Leukemia (ALL)
-
2024-512470-10-00
11
2018-02-02
End-stage Renal disease
-
2024-514417-34-00
5
2017-12-14
Cancer
-
2024-512212-21-00
5
2017-11-28
Advanced hepatocellular carcinoma (HCC)
-
2023-510444-21-00
5
2017-11-24
Neuroendocrine tumours of gastroenteric or pancreatic origin
-
2024-516112-21-00
5
2017-11-20
Newly diagnosed acute myeloid leukaemia (AML), high risk myelodysplast
-
2024-516601-23-00
5
2017-11-14
Colorectal adenomas
-
2023-503438-40-00
7
2017-10-05
Relapsed/Refractory Multiple Myeloma
-
2024-515499-12-00
5
2017-10-02
Acute lymphoblastic leukemia
-
2024-513964-24-00
5
2017-09-14
Squamous cell carcinoma, previously untreated
Stage III, stage IVa (op
-
2024-515119-23-00
9
2017-08-29
Phase Ib and Phase II part 1: HPV-16 positive recurrent or metastatic
-
2023-504951-29-00
5
2017-07-27
Chron's Disease